UNSPSC 51282419: Carindacillin sodium

This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C26H25N2O6S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4OUL81K2RT, chemically known as 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((3-((2,3-dihydro-1h-inden-5-yl)oxy)-1,3-dioxo-2-phenylpropyl)amino)-3,3-dimethyl-7-oxo-, monosodium salt, (2s-(2alpha,5alpha,6beta))- but more generally known as carbenicillin indanyl sodium, which bears US NIH Compound Identifier 33554.

UNSPSC 51282419 Carindacillin sodium is a Commodity code for a specific antibiotic pharmaceutical product. State and local procurement activity under this code shows minimal recent volume; the opportunities available do not consistently or primarily source carindacillin sodium itself, but instead reflect broader pharmaceutical acquisition through piggyback and cooperative purchasing contracts where multiple drugs—including antibiotics, naloxone, and drug deactivation supplies—are bundled under single procurement vehicles. State health departments and county public health authorities are the primary issuing bodies, typically procuring pharmaceuticals through established consortiums or fixed-price competitive bidding to support emergency preparedness, community health, and harm-reduction initiatives.

Activity concentrates in Florida and Illinois. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, covering Doxycycline Hyclate and Ciprofloxacin Hydrochloride over a 12-month initial term with two renewal options. Seminole County, Florida issued an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a July 26, 2023 response deadline, requiring quarterly deliveries and including vendor responsibility for shipping. Neither recent opportunity explicitly solicits carindacillin sodium as a line item, suggesting the code may be tagged broadly to pharmaceutical procurement categories rather than pinpointing demand for this specific product. Firms pursuing this code should expect activity concentrated in state health departments and county health authorities using cooperative purchasing or piggyback vehicles rather than direct single-product solicitations.